MX2016000271A - Metodos para el tratamiento de la esofagitis eosinofilica mediante la administracion de un inhibidor de il-4r. - Google Patents

Metodos para el tratamiento de la esofagitis eosinofilica mediante la administracion de un inhibidor de il-4r.

Info

Publication number
MX2016000271A
MX2016000271A MX2016000271A MX2016000271A MX2016000271A MX 2016000271 A MX2016000271 A MX 2016000271A MX 2016000271 A MX2016000271 A MX 2016000271A MX 2016000271 A MX2016000271 A MX 2016000271A MX 2016000271 A MX2016000271 A MX 2016000271A
Authority
MX
Mexico
Prior art keywords
methods
inhibitor
administration
treatment
eosinophilic esophagitis
Prior art date
Application number
MX2016000271A
Other languages
English (en)
Other versions
MX380220B (es
Inventor
Ana Kostic
Ludmila Kelly
Brendan J Classon
Xia Liu
Original Assignee
Regeneron Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Regeneron Pharma filed Critical Regeneron Pharma
Publication of MX2016000271A publication Critical patent/MX2016000271A/es
Publication of MX380220B publication Critical patent/MX380220B/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/06—Anti-spasmodics, e.g. drugs for colics, esophagic dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/12—Antidiarrhoeals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A61K2039/577—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 tolerising response
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2318/00—Antibody mimetics or scaffolds

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Pulmonology (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Dermatology (AREA)
  • Endocrinology (AREA)
  • Nutrition Science (AREA)
  • Hospice & Palliative Care (AREA)
  • Otolaryngology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

La presente invención proporciona métodos para tratar, prevenir o reducir la gravedad de la esofagitis eosinofílica. Los métodos de la presente invención comprenden administrar a un sujeto que lo necesite una composición terapéutica que comprende un inhibidor del receptor de interleuquina-4 (lL-4Ra) tal como un anticuerpo anti-IL-4Ra.
MX2016000271A 2013-07-11 2014-07-10 Composiciones farmacéuticas que comprenden un inhibidor de il-4r para usarse en el tratamiento de la esofagitis eosinofílica. MX380220B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201361844978P 2013-07-11 2013-07-11
PCT/US2014/046170 WO2015006571A1 (en) 2013-07-11 2014-07-10 Methods for treating eosinophilic esophagitis by administering an il-4r inhibitor

Publications (2)

Publication Number Publication Date
MX2016000271A true MX2016000271A (es) 2016-04-20
MX380220B MX380220B (es) 2025-03-12

Family

ID=51298948

Family Applications (2)

Application Number Title Priority Date Filing Date
MX2016000271A MX380220B (es) 2013-07-11 2014-07-10 Composiciones farmacéuticas que comprenden un inhibidor de il-4r para usarse en el tratamiento de la esofagitis eosinofílica.
MX2021002406A MX2021002406A (es) 2013-07-11 2016-01-08 Composiciones farmaceuticas que comprenden un inhibidor de il-4r para usarse en el tratamiento de la esofagitis eosinofilica.

Family Applications After (1)

Application Number Title Priority Date Filing Date
MX2021002406A MX2021002406A (es) 2013-07-11 2016-01-08 Composiciones farmaceuticas que comprenden un inhibidor de il-4r para usarse en el tratamiento de la esofagitis eosinofilica.

Country Status (25)

Country Link
US (4) US9290574B2 (es)
EP (2) EP3659623A1 (es)
JP (2) JP6576339B2 (es)
KR (2) KR102398718B1 (es)
CN (2) CN105392497B (es)
AU (2) AU2014287196B2 (es)
CA (1) CA2917804C (es)
CY (1) CY1122909T1 (es)
DK (1) DK3019191T3 (es)
ES (1) ES2778902T3 (es)
HR (1) HRP20200628T1 (es)
HU (1) HUE049442T2 (es)
IL (1) IL279499B (es)
LT (1) LT3019191T (es)
MX (2) MX380220B (es)
NZ (1) NZ631031A (es)
PL (1) PL3019191T3 (es)
PT (1) PT3019191T (es)
RS (1) RS60151B1 (es)
RU (1) RU2679141C2 (es)
SG (2) SG10201802344YA (es)
SI (1) SI3019191T1 (es)
TW (2) TWI634900B (es)
WO (1) WO2015006571A1 (es)
ZA (1) ZA201508717B (es)

Families Citing this family (53)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7608693B2 (en) 2006-10-02 2009-10-27 Regeneron Pharmaceuticals, Inc. High affinity human antibodies to human IL-4 receptor
CN106421797A (zh) 2009-10-01 2017-02-22 艾戴尔医药公司 口服给予的皮质类固醇组合物
WO2014031610A1 (en) 2012-08-21 2014-02-27 Sanofi Methods for treating or preventing asthma by administering an il-4r antagonist
HRP20181227T1 (hr) 2012-09-07 2018-10-05 Regeneron Pharmaceuticals, Inc. Metode za liječenje atopijskog dermatitisa primjenom antagonista il-4r
TWI755763B (zh) 2013-06-04 2022-02-21 美商再生元醫藥公司 藉由投與il-4r抑制劑以治療過敏及增強過敏原-特異之免疫療法的方法
TWI634900B (zh) 2013-07-11 2018-09-11 再生元醫藥公司 藉由投與ｉｌ－４ｒ抑制劑治療嗜酸性食道炎的方法
WO2015034678A2 (en) 2013-09-06 2015-03-12 Aptalis Pharmatech, Inc. Corticosteroid containing orally disintegrating tablet compositions for eosinophilic esophagitis
RU2704999C2 (ru) 2014-02-28 2019-11-01 Ридженерон Фармасьютикалз, Инк. Способ лечения кожной инфекции путем введения антагониста il-4r
US10066017B2 (en) 2014-11-14 2018-09-04 Sanofi Biotechnology Methods for treating chronic sinusitis with nasal polyps by administering an IL-4R antagonist
PT3277722T (pt) * 2015-04-02 2021-10-06 Intervet Int Bv Anticorpos para recetor alfa da interleucina-4 canina
WO2017102920A1 (en) 2015-12-18 2017-06-22 Intervet International B.V. Caninized human antibodies to human and canine il-4r alpha
US11091556B2 (en) 2015-12-18 2021-08-17 Intervet Inc. Caninized human antibodies to human IL-4R alpha
EA037960B1 (ru) 2016-04-27 2021-06-15 Эббви Инк. Способ лечения эозинофильного эзофагита с применением антитела против il-13
CN107474134B (zh) 2016-06-08 2021-07-27 苏州康乃德生物医药有限公司 用于结合白细胞介素4受体的抗体
TWI777515B (zh) 2016-08-18 2022-09-11 美商愛戴爾製藥股份有限公司 治療嗜伊紅性食道炎之方法
CN109789196B (zh) * 2016-09-01 2024-03-19 瑞泽恩制药公司 用于通过施用il-4r拮抗剂来预防或治疗变态反应的方法
JP2019193577A (ja) * 2016-09-01 2019-11-07 国立研究開発法人国立成育医療研究センター 好酸球性消化管疾患または食物蛋白誘発腸症の検査方法および検査キット
CN118203659A (zh) * 2016-09-22 2024-06-18 瑞泽恩制药公司 用于通过施用il-4r抑制剂治疗严重特应性皮炎的方法
TWI857389B (zh) 2016-12-01 2024-10-01 美商再生元醫藥公司 治療發炎症狀的方法
MX2019012171A (es) 2017-04-13 2019-11-25 Regeneron Pharma Tratamiento e inhibicion de enfermedades pulmonares inflamatorias en pacientes que tienen alelos de riesgo en los genes que codifican la il33 e il1rl1.
CN111246880A (zh) * 2017-05-05 2020-06-05 爱乐科斯公司 用于治疗炎性胃肠道障碍的方法和组合物
WO2019028367A1 (en) * 2017-08-04 2019-02-07 Regeneron Pharmaceuticals, Inc. METHODS OF TREATING ESOPHAGITIS WITH ACTIVE EOSINOPHILES
IL315556A (en) * 2017-08-04 2024-11-01 Regeneron Pharma Methods for treating active eosinophilic esophagitis
PT3515465T (pt) 2017-08-18 2024-03-04 Regeneron Pharma Métodos para o tratamento de uma dermatite atópica grave mediante a administração de um inibidor de il-4r
PL3703818T3 (pl) 2017-10-30 2024-03-25 Sanofi Biotechnology Antagonista IL-4R do zastosowania w sposobie leczenia lub zapobiegania astmie
BR112020012830A2 (pt) 2017-12-29 2021-01-26 Cornell University terapia genética para distúrbios eosinofílicos
KR102652133B1 (ko) * 2018-02-01 2024-03-29 베이징 카윈 테크놀로지 쉐어-홀딩 컴퍼니 리미티드 IL-4Rα 항체 및 그 용도
WO2019165138A1 (en) * 2018-02-21 2019-08-29 Adare Development I, L.P. Methods of managing eosinophilic esophagitis
EP3793597A1 (en) 2018-05-13 2021-03-24 Regeneron Pharmaceuticals, Inc. Methods for treating atopic dermatitis by administering an il-4r inhibitor
CN113101364B (zh) 2018-05-29 2023-12-01 康诺亚生物医药科技（成都）有限公司 一种自免疫抑制剂的开发和应用
CN110872349A (zh) * 2018-09-04 2020-03-10 三生国健药业（上海）股份有限公司 结合人il-4r的抗体、其制备方法和用途
CN111494625B (zh) 2018-12-25 2022-06-21 江苏荃信生物医药股份有限公司 用于治疗il-4和/或il-13介导的信号转导相关的疾病的药物组合物
CN111647082B (zh) * 2018-12-27 2023-02-17 中山康方生物医药有限公司 抗人il-4ra的抗体及其用途
MA55372A (fr) 2019-03-21 2022-01-26 Regeneron Pharma Combinaison d'inhibiteurs de la voie il-4/il-13 et d'ablation de plasmocytes pour traiter une allergie
JP7592064B2 (ja) 2019-07-16 2024-11-29 サノフィ・バイオテクノロジー Ｉｌ－４ｒアンタゴニストを投与することにより喘息を治療するまたは予防するための方法
AU2020326713A1 (en) 2019-08-05 2022-02-17 Regeneron Pharmaceuticals, Inc. Methods for treating atopic dermatitis by administering an il-4r antagonist
CN114173819A (zh) 2019-08-05 2022-03-11 瑞泽恩制药公司 通过施用il-4r拮抗剂治疗过敏和增强过敏原特异性免疫疗法的方法
EP4073810A1 (en) * 2019-12-09 2022-10-19 Sanofi Biotechnology Methods for treating digitally-identified il-4/il-13 related disorders
EP3992974A1 (en) 2020-11-02 2022-05-04 Sanofi Biotechnology Methods for treating digitally-identified il-4/il-13 related disorders
CN114829396A (zh) 2019-12-20 2022-07-29 英特维特国际股份有限公司 用于治疗特应性皮炎的双特异性犬源化抗体和双特异性结合伴体
WO2021123089A1 (en) 2019-12-20 2021-06-24 Intervet International B.V. Antibodies to canine interleukin-4 receptor alpha
KR20230015965A (ko) * 2020-05-22 2023-01-31 리제너론 파아마슈티컬스, 인크. Il-4r 억제제를 투여함에 의해 호산구성 식도염을 치료하기 위한 방법
US12577310B2 (en) 2020-10-15 2026-03-17 Intervet Inc. Caninized antibodies to canine interleukin-31 receptor alpha
EP4240350A4 (en) * 2020-11-09 2024-09-18 Arena Pharmaceuticals, Inc. <sup2/>? <sub2/>?1?methods of treating conditions related to the s1preceptor
CN114805572B (zh) * 2021-01-22 2022-12-13 上海济煜医药科技有限公司 抗原结合蛋白及其应用
CA3208011A1 (en) 2021-03-17 2022-09-22 Sarah Harris Methods of treating atopic dermatitis with anti il-13 antibodies
EP4388006A1 (en) 2021-08-20 2024-06-26 Intervet International B.V. Homodimer fusion proteins for treating atopic dermatitis
KR20250007616A (ko) * 2022-04-29 2025-01-14 아케소 바이오파마, 인크. 항-인간 il-4ra 항체 및 이의 용도
MA71395A (fr) * 2022-07-08 2025-04-30 Regeneron Pharmaceuticals, Inc. Méthodes de traitement de l'oesophagite à éosinophiles chez un sujet pédiatrique par administration d'un antagoniste d'il-4 r
JP2026508149A (ja) 2023-02-13 2026-03-10 インターベット インターナショナル ベー． フェー． イヌｉｌ－１３に対するイヌ抗体
CN120897928A (zh) 2023-02-13 2025-11-04 英特维特国际股份有限公司 针对犬il-4的犬抗体
EP4665757A2 (en) * 2023-02-17 2025-12-24 Apogee Therapeutics, Inc. Antibodies that bind interleukin 4 receptor alpha and methods of use
US20250230251A1 (en) 2023-12-20 2025-07-17 Bristol-Myers Squibb Company Antibodies targeting il-18 receptor beta (il-18rb) and related methods

Family Cites Families (101)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8808015D0 (en) 1988-04-06 1988-05-05 Ritter M A Chemical compounds
AU643427B2 (en) 1988-10-31 1993-11-18 Immunex Corporation Interleukin-4 receptors
AU665763B2 (en) 1991-05-03 1996-01-18 Seragen, Inc. Interleukin receptor targeted molecules for treatment of inflammatory arthritis
JP3315427B2 (ja) 1992-03-05 2002-08-19 大日本除蟲菊株式会社 皮膚炎治療剤
US5714146A (en) 1992-08-26 1998-02-03 Board Of Regents Of The University Of Washington IL-4 bone therapy
EP0604693A1 (en) 1992-12-29 1994-07-06 Schering-Plough Monoclonal antibodies against the human interleukin-4 receptor and hybridomas producing the same
RU2162711C2 (ru) 1993-09-07 2001-02-10 Смитклайн Бичам Корпорейшн Рекомбинантные il4-антитела, используемые для лечения нарушений, связанных с действием il4
US6849614B1 (en) 1998-07-28 2005-02-01 Ecosmart Technologies, Inc. Synergistic and residual pesticidal compositions containing plant essential oils
ES2259478T3 (es) 1998-09-18 2006-10-01 Dynavax Technologies Corporation Metodos para tratar trastornos asociados con la ige y composiciones para este uso.
DE16192152T1 (de) 2000-05-26 2020-08-06 Immunex Corporation Verwendung von interleukin-4 rezeptor (il-4r) antikörpern und zusammensetzungen davon
US7879328B2 (en) 2000-06-16 2011-02-01 Human Genome Sciences, Inc. Antibodies that immunospecifically bind to B lymphocyte stimulator
DE60130466T2 (de) 2000-07-26 2008-06-12 Hououdou Co. Ltd. Antipruritische zusammensetzungen und die wundheilung fördernde zusammensetzungen
US6391531B1 (en) 2000-11-06 2002-05-21 Eastman Kodak Company Low silver radiographic film and imaging assembly for thoracic imaging
RU2283665C2 (ru) 2000-12-22 2006-09-20 Сосьете Де Продюи Нестле С.А. Индуцирование толерантности
US20030103938A1 (en) 2001-05-09 2003-06-05 Alk-Abello A/S Pharmaceutical compositions for preventing or treating Th1 and Th2 cell related diseases by modulating the Th1/Th2 ratio
EP1390067A1 (en) 2001-05-11 2004-02-25 Novartis AG Compositions for use in treating ige-associated disorders
CA2447795A1 (en) 2001-05-23 2002-11-28 Duotol Ab Suppression of allergic reactions by transdermal administration of allergens in conjunction with or conjugated to toxin subunits or fragments thereof
DK1461300T3 (da) 2001-11-30 2011-10-24 Biogen Idec Inc Antistoffer mod kemotaktiske monocytproteiner
CN1326879C (zh) 2002-03-29 2007-07-18 先灵公司 人源抗白细胞介素5单克隆抗体及其制备方法和包含这些抗体的组合物
EP1581166A2 (en) * 2003-01-07 2005-10-05 Children's Hospital Medical Center Cytokine inhibition of eosinophils
ES2575547T3 (es) 2003-02-01 2016-06-29 Tanox, Inc. Anticuerpos anti-IgE de humano de alta afinidad
US7923209B2 (en) 2003-03-14 2011-04-12 Anergis, S.A. Allergen peptide fragments and use thereof
GEP20104991B (en) 2003-11-07 2010-05-25 Immunex Corp Antibodies that bind interleukin-4 receptor
AU2004309373A1 (en) 2003-12-22 2005-07-14 Amgen Inc. Methods for identifying functional antibodies
CN1922204A (zh) * 2004-02-27 2007-02-28 瑞泽恩制药公司 Il－4/il－13特异性的多肽和其治疗应用
CA2554596A1 (en) 2004-02-27 2005-09-15 Regeneron Pharmaceuticals, Inc. Il-4/il-13 specific polypetides and therapeutic uses thereof
JP4365697B2 (ja) 2004-03-05 2009-11-18 三菱重工業株式会社 印刷機の廃液再生装置及び廃液再生方法
US20090098142A1 (en) 2004-06-09 2009-04-16 Kasaian Marion T Methods and compositions for treating and monitoring treatment of IL-13-associated disorders
TWI307630B (en) 2004-07-01 2009-03-21 Glaxo Group Ltd Immunoglobulins
JP5234445B2 (ja) 2004-10-05 2013-07-10 源一郎 杣 薬剤
WO2006083390A2 (en) 2004-12-07 2006-08-10 Children's Hospital Medical Center Eotaxin-3 in eosinophilic esophagitis
US8592548B2 (en) 2004-12-22 2013-11-26 Sabic Innovative Plastics Ip B.V. Method to prepare bis(haloimides)
TW200902555A (en) 2005-01-03 2009-01-16 Hoffmann La Roche Antibodies against IL-13 receptor alpha 1 and uses thereof
US8324192B2 (en) 2005-11-12 2012-12-04 The Regents Of The University Of California Viscous budesonide for the treatment of inflammatory diseases of the gastrointestinal tract
US8679545B2 (en) 2005-11-12 2014-03-25 The Regents Of The University Of California Topical corticosteroids for the treatment of inflammatory diseases of the gastrointestinal tract
JP4221018B2 (ja) 2006-08-31 2009-02-12 トヨタ自動車株式会社 頭部保護エアバッグ装置
WO2008054606A2 (en) 2006-10-02 2008-05-08 Regeneron Pharmaceuticals, Inc. High affinity human antibodies to human il-4 receptor
US7608693B2 (en) 2006-10-02 2009-10-27 Regeneron Pharmaceuticals, Inc. High affinity human antibodies to human IL-4 receptor
KR100844828B1 (ko) 2006-11-24 2008-07-08 주식회사알에프윈도우 안테나를 내장한 궤환 간섭신호 제거 무선중계장치
RU2500686C2 (ru) 2007-03-22 2013-12-10 Дженентек, Инк. АПОПТОТИЧЕСКИЕ АНТИТЕЛА ПРОТИВ IgE
EP2022507A1 (en) 2007-08-07 2009-02-11 Universität Hamburg Antibody compositions specific for lgE, lgG4 and lgA epitopes as tools for the design of hypoallergenic molecules for specific immunotherapy
WO2009061819A1 (en) 2007-11-05 2009-05-14 The Regents Of The University Of Colorado Minimally-invasive measurement of esophageal inflammation
US8092804B2 (en) 2007-12-21 2012-01-10 Medimmune Limited Binding members for interleukin-4 receptor alpha (IL-4Rα)-173
DE202008006598U1 (de) 2008-04-11 2008-10-02 Alk-Abelló A/S Allergie-Impfstoff-Formulierung zur mucosalen Verabreichung
US20090264392A1 (en) 2008-04-21 2009-10-22 Meritage Pharma, Inc. Treating eosinophilic esophagitis
EP2376656A4 (en) 2008-12-01 2012-05-16 Cincinnati Children S Hospital Medical Ct METHOD AND DETERMINATION OF THE EFFECTIVENESS OF A GLUCOCORTICOID TREATMENT OF EOSINOPHILIAN ESOPHAGITIS
EP2414520A2 (en) 2009-03-31 2012-02-08 Altair Therapeutics, Inc. Methods of modulating an immune response to a viral infection
FR2946632B1 (fr) 2009-06-11 2015-05-29 Sidel Participations Installation de convoyage comprenant au moins un couloir courbe
US8497528B2 (en) 2010-05-06 2013-07-30 Taiwan Semiconductor Manufacturing Company, Ltd. Method for fabricating a strained structure
AU2010291171B2 (en) 2009-09-07 2015-10-29 Dbv Technologies Method of treating eosinophilic esophagitis
US8993347B2 (en) 2009-12-17 2015-03-31 Cornell University Methods for detecting antibodies in mucosal samples and device for sampling mucosal material
WO2011163614A2 (en) 2010-06-24 2011-12-29 Meritage Pharma, Inc. Methods of treatment for esophageal inflammation
PL2624865T3 (pl) 2010-10-06 2018-11-30 Regeneron Pharmaceuticals, Inc. Stabilizowane preparaty zawierające przeciwciała przeciwko receptorowi interleukiny-4 (IL-4R)
JP6013915B2 (ja) 2010-11-17 2016-10-25 中外製薬株式会社 血液凝固第ｖｉｉｉ因子の機能を代替する機能を有する多重特異性抗原結合分子
RU2453303C1 (ru) 2010-12-23 2012-06-20 Общество с ограниченной ответственностью "ЦитоНИР" (ООО "ЦитоНИР") Фармацевтическая композиция для лечения атопического дерматита
CA2824043A1 (en) 2011-01-06 2012-07-12 Marc E. Rothenberg Esophageal cytokine expression profiles in eosinophilic esophagitis
US20130052190A1 (en) 2011-02-22 2013-02-28 Oxagen Limited CRTH2 Antagonists for Treatment of Eosinophilic Diseases and Conditions
AU2012272858B2 (en) 2011-06-21 2017-03-09 Children's Hospital Medical Center Diagnostic methods for eosinophilic esophagitis
US8790651B2 (en) 2011-07-21 2014-07-29 Zoetis Llc Interleukin-31 monoclonal antibody
CN103974706A (zh) 2011-10-06 2014-08-06 N·V·努特里奇亚 嗜酸细胞性食管炎的治疗
SG11201402796SA (en) * 2011-12-16 2014-06-27 Atopix Therapeutics Ltd Combination of crth2 antagonist and a proton pump inhibitor for the treatment of eosinophilic esophagitis
AR091305A1 (es) 2012-01-31 2015-01-28 Genentech Inc ANTICUERPOS ANTI-IgE Y SUS METODOS DE USO
WO2013155010A1 (en) 2012-04-09 2013-10-17 Children's Hospital Medical Center Non-invasive biomarkers for eosinophilic esophagitis
WO2014031610A1 (en) 2012-08-21 2014-02-27 Sanofi Methods for treating or preventing asthma by administering an il-4r antagonist
HRP20181227T1 (hr) 2012-09-07 2018-10-05 Regeneron Pharmaceuticals, Inc. Metode za liječenje atopijskog dermatitisa primjenom antagonista il-4r
WO2014059178A1 (en) 2012-10-10 2014-04-17 Rhode Island Hospital Differential expression of novel protein markers for the diagnosis and treatment of eosinophilic esophagitis
ES2667420T3 (es) 2013-02-05 2018-05-10 Engmab Sàrl Anticuerpos biespecíficos contra cd3epsilon y bcma
TWI755763B (zh) 2013-06-04 2022-02-21 美商再生元醫藥公司 藉由投與il-4r抑制劑以治療過敏及增強過敏原-特異之免疫療法的方法
TWI634900B (zh) 2013-07-11 2018-09-11 再生元醫藥公司 藉由投與ｉｌ－４ｒ抑制劑治療嗜酸性食道炎的方法
BR112016008694A2 (pt) 2013-10-23 2017-10-03 Genentech Inc Métodos de previsão da reação de pacientes com asma, de previsão da capacidade de reação de pacientes com asma, de identificação de pacientes com asma, de tratamento de pacientes portadores de asma e de tratamento de asma, uso de um kit e kit
RU2552929C1 (ru) 2013-11-14 2015-06-10 Общество С Ограниченной Ответственностью "Фарминтерпрайсез" Фармацевтическая композиция, содержащая производные глутаримидов, и их применение для лечения эозинофильных заболеваний
IL315136A (en) 2014-02-21 2024-10-01 Sanofi Biotechnology Methods for treating or preventing asthma by administering an il-4rantagonist
RU2704999C2 (ru) 2014-02-28 2019-11-01 Ридженерон Фармасьютикалз, Инк. Способ лечения кожной инфекции путем введения антагониста il-4r
PT3613432T (pt) 2014-05-07 2025-10-29 Regeneron Pharma Métodos para tratar a polipose nasal através da administração de um antagonista de il-4r
US10066017B2 (en) 2014-11-14 2018-09-04 Sanofi Biotechnology Methods for treating chronic sinusitis with nasal polyps by administering an IL-4R antagonist
CA2978026A1 (en) 2015-03-11 2016-09-15 Glaxosmithkline Intellectual Property Development Limited Tslp binding proteins
MA44238B1 (fr) 2016-02-19 2024-07-31 Regeneron Pharmaceuticals, Inc. Procédés d'augmentation de l'efficacité d'un vaccin par administration d'un antagoniste d'il-4r
EA037960B1 (ru) 2016-04-27 2021-06-15 Эббви Инк. Способ лечения эозинофильного эзофагита с применением антитела против il-13
TWI777515B (zh) 2016-08-18 2022-09-11 美商愛戴爾製藥股份有限公司 治療嗜伊紅性食道炎之方法
CN109789196B (zh) 2016-09-01 2024-03-19 瑞泽恩制药公司 用于通过施用il-4r拮抗剂来预防或治疗变态反应的方法
CN118203659A (zh) 2016-09-22 2024-06-18 瑞泽恩制药公司 用于通过施用il-4r抑制剂治疗严重特应性皮炎的方法
CN110461335A (zh) 2017-02-17 2019-11-15 弗雷德哈钦森癌症研究中心 用于治疗bcma相关癌症和自身免疫性失调的联合疗法
US20200179511A1 (en) 2017-04-28 2020-06-11 Novartis Ag Bcma-targeting agent, and combination therapy with a gamma secretase inhibitor
CN111246880A (zh) 2017-05-05 2020-06-05 爱乐科斯公司 用于治疗炎性胃肠道障碍的方法和组合物
WO2019028367A1 (en) 2017-08-04 2019-02-07 Regeneron Pharmaceuticals, Inc. METHODS OF TREATING ESOPHAGITIS WITH ACTIVE EOSINOPHILES
PT3515465T (pt) 2017-08-18 2024-03-04 Regeneron Pharma Métodos para o tratamento de uma dermatite atópica grave mediante a administração de um inibidor de il-4r
RU2698048C2 (ru) 2017-10-03 2019-08-21 Закрытое Акционерное Общество "Биокад" МОНОКЛОНАЛЬНОЕ АНТИТЕЛО К IL-5Rα
PL3703818T3 (pl) 2017-10-30 2024-03-25 Sanofi Biotechnology Antagonista IL-4R do zastosowania w sposobie leczenia lub zapobiegania astmie
WO2019165138A1 (en) 2018-02-21 2019-08-29 Adare Development I, L.P. Methods of managing eosinophilic esophagitis
EP3793597A1 (en) 2018-05-13 2021-03-24 Regeneron Pharmaceuticals, Inc. Methods for treating atopic dermatitis by administering an il-4r inhibitor
KR102880460B1 (ko) 2018-06-14 2025-11-06 아지노모토 가부시키가이샤 항체에 대한 친화성 물질 및 생체 직교성 관능기를 갖는 화합물 또는 이의 염
MA55372A (fr) 2019-03-21 2022-01-26 Regeneron Pharma Combinaison d'inhibiteurs de la voie il-4/il-13 et d'ablation de plasmocytes pour traiter une allergie
AU2020326713A1 (en) 2019-08-05 2022-02-17 Regeneron Pharmaceuticals, Inc. Methods for treating atopic dermatitis by administering an il-4r antagonist
CN114173819A (zh) 2019-08-05 2022-03-11 瑞泽恩制药公司 通过施用il-4r拮抗剂治疗过敏和增强过敏原特异性免疫疗法的方法
EP4073810A1 (en) 2019-12-09 2022-10-19 Sanofi Biotechnology Methods for treating digitally-identified il-4/il-13 related disorders
WO2021195530A1 (en) 2020-03-27 2021-09-30 Regeneron Pharmaceuticals, Inc. Methods for treating atopic dermatitis by administering an il-4r antagonist
KR20230015965A (ko) 2020-05-22 2023-01-31 리제너론 파아마슈티컬스, 인크. Il-4r 억제제를 투여함에 의해 호산구성 식도염을 치료하기 위한 방법
US20220169739A1 (en) 2020-10-05 2022-06-02 Sanofi Biotechnology Methods for treating asthma in pediatric subjects by administering an il-4r antagonist
WO2022150605A1 (en) 2021-01-08 2022-07-14 Regeneron Pharmaceuticals, Inc. Methods for treating peanut allergy and enhancing peanut allergen-specific immunotherapy by administering an il-4r antagonist
MA71395A (fr) 2022-07-08 2025-04-30 Regeneron Pharmaceuticals, Inc. Méthodes de traitement de l'oesophagite à éosinophiles chez un sujet pédiatrique par administration d'un antagoniste d'il-4 r
TW202502820A (zh) 2023-03-27 2025-01-16 美商再生元醫藥公司 藉由投予ｉｌ—４ｒ拮抗劑治療嗜酸性球性胃腸炎之方法

Also Published As

Publication number Publication date
DK3019191T3 (da) 2020-04-27
HUE049442T2 (hu) 2020-09-28
ZA201508717B (en) 2017-03-29
LT3019191T (lt) 2020-03-10
HRP20200628T1 (hr) 2020-07-10
CN111939261A (zh) 2020-11-17
US10730948B2 (en) 2020-08-04
US20150017176A1 (en) 2015-01-15
JP6837105B2 (ja) 2021-03-03
CN111939261B (zh) 2022-10-11
SG10201802344YA (en) 2018-05-30
CA2917804A1 (en) 2015-01-15
NZ631031A (en) 2017-09-29
US12291571B2 (en) 2025-05-06
TW201545756A (zh) 2015-12-16
PL3019191T3 (pl) 2020-07-27
PT3019191T (pt) 2020-03-05
US20160152718A1 (en) 2016-06-02
EP3659623A1 (en) 2020-06-03
MX380220B (es) 2025-03-12
US11421036B2 (en) 2022-08-23
IL279499B (en) 2021-08-31
US9290574B2 (en) 2016-03-22
RU2679141C2 (ru) 2019-02-06
WO2015006571A1 (en) 2015-01-15
KR102398718B1 (ko) 2022-05-17
EP3019191A1 (en) 2016-05-18
AU2014287196A1 (en) 2016-01-07
CN105392497B (zh) 2020-09-11
TW201838653A (zh) 2018-11-01
ES2778902T3 (es) 2020-08-12
SI3019191T1 (sl) 2020-04-30
RU2016104400A (ru) 2017-08-16
TWI682781B (zh) 2020-01-21
CN105392497A (zh) 2016-03-09
JP6576339B2 (ja) 2019-09-18
AU2014287196B2 (en) 2019-10-24
JP2016528207A (ja) 2016-09-15
KR20210145852A (ko) 2021-12-02
KR20160029750A (ko) 2016-03-15
US20200332014A1 (en) 2020-10-22
CY1122909T1 (el) 2021-10-29
TWI634900B (zh) 2018-09-11
JP2019214600A (ja) 2019-12-19
CA2917804C (en) 2021-11-16
EP3019191B1 (en) 2020-02-12
RS60151B1 (sr) 2020-05-29
WO2015006571A8 (en) 2019-08-08
US20230272085A1 (en) 2023-08-31
AU2020200497B2 (en) 2022-02-03
HK1218854A1 (en) 2017-03-17
SG11201509698SA (en) 2015-12-30
KR102333268B1 (ko) 2021-12-03
MX2021002406A (es) 2021-05-13
IL279499A (en) 2021-01-31
AU2020200497A1 (en) 2020-02-13

Similar Documents

Publication Publication Date Title
MX2016000271A (es) Metodos para el tratamiento de la esofagitis eosinofilica mediante la administracion de un inhibidor de il-4r.
MX2024013963A (es) Un antagonista de il-4r util para el tratamiento o la prevencion del asma
PY1337526A (es) Métodos para tratar o prevenir asma administrando un antagonista de IL-4R.
MX2021008113A (es) Composiciones farmaceuticas que comprenden un antagonista de il-4r para usarse en el tratamiento del asma.
MX2019009853A (es) Terapia de combinacion que incluye un inhibidor mdm2 y uno o mas agentes farmaceuticamente activos adicionales para el tratamiento de canceres.
CL2017003456A1 (es) Metodos para tratar tumores de celulas epitelioides
MX2017010773A (es) Inhibidores de muerte programada 1 (pd-19)/ligando de muerte progamada 1 (pd-l1) para el tratamiento de cancer.
GT201700167A (es) Terapias de combinación para el tratamiento de cánceres.
MX2016002077A (es) Inhibidores de la proteína regulada por glucosa 94 (gpr94) selectivos y usos de los mismos.
CR20150376A (es) Compuestos sustituidos de pirrolopirimidina, compuestos de los mismos y metodos de tratamiento con los mismos
UY35210A (es) Inhibidores de autotaxina
NI201600071A (es) Compuestos de inhibidor de autotaxina
AR092475A1 (es) Metodos para tratar la dermatitis atopica mediante la administracion de un antagonista de il-4r
MX2016011810A (es) Composiciones farmaceuticas de compuestos terapeuticamente activos y sus metodos de uso.
UY35493A (es) Métodos para el tratamiento de la osteogénesis imperfecta
MX2016005294A (es) Metodos para tratar y prevenir enfermedad injerto contra huésped.
ECSP17059323A (es) Formulacion de combinacion de tesofensina y betabloqueante
MX2017011018A (es) Inhibicion de la actividad de olig2.
AR102871A1 (es) Métodos de tratamiento de fibrosis
UY35823A (es) Profármacos de antagonista de nmda
BR112016012248A2 (pt) método de tratamento de nefropatia
MX381429B (es) Tricostatina a (tsa) para usarse en el tratamiento del cáncer.
MX2016002308A (es) Tratamiento del mieloma multiple.
MX2017003140A (es) Tratamiento de los sintomas asociados a terapia privacion de androgenos.
UY35033A (es) Formulación en comprimidos de un inhibidor de la fosfatidilinositol 3-cinasa